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Pyrimidine nucleoside phosphorylase (PyNPase), distributed
mainly as thymidine phosphorylase in humans (Kono et al, 1983),
is an enzyme involved in the salvage pathway of pyrimidine
nucleotide synthesis (Weber, 1983). 5¢-Deoxy-5-fluorouridine (5¢-
DFUR), a prodrug of 5-fluorouracil (5-FU), is converted to 5-FU
by this enzyme (Ishitsuka et al, 1980; Eda et al, 1993). As a result,
PyNPase plays an important role in the expression of the anti-
tumour activity of 5-DFUR. In contrast, PyNPase has also been
recently shown to be identical to a potent angiogenic factor,
platelet-derived endothelial cell growth factor (PD-ECGF), which
is thought to influence angiogenesis in tumour tissue (Ishikawa et
al, 1989; Furukawa et al, 1992).
Previous studies have suggested the expression of PyNPase to
be higher in malignant tissue than in normal tissue in several kinds
of carcinomas, such as lung carcinomas, colorectal carcinomas,
gastric carcinomas and so on (Nio et al, 1992; Luccioni et al, 1994;
Takebayashi et al, 1996a—c; Giatromanolaki et al, 1997). The high
expressions of PyNPase have also been revealed to be related to a
high invasive potential or poor prognosis in carcinomas, including
colorectal carcinoma, gastric carcinoma, renal cell carcinoma and
bladder carcinoma (Takebayashi et al, 1996a,b; Imazono et al,
1997; Kubota et al 1997; Mimori et al, 1997). However, there
have been few reports concerning the expression of PyNPase
in oesophageal carcinoma. Thus, the clinical significance of
higher PyNPase activity in oesophageal carcinoma has yet to be
clarified.
Because the reverse transcription polymerase chain reaction
(RT-PCR) method can amplify a target mRNA from a small
amount of sample such as that obtained from a few biopsy speci-
mens (Hirokoshi et al, 1992), this assay method is thus preferable
to an enzyme assay which needs large samples of more than
100 mg (Eda et al, 1993). Mimori et al (1997) showed a positive
correlation to exist between the expression of PyNPase mRNA by
RT-PCR and the enzyme activity of PyNPase in colorectal carci-
noma. The aim of the present study was, thus, to confirm the corre-
lation between PyNPase mRNA and the enzyme level of PyNPase
in oesophageal carcinoma, and to also demonstrate the clinical
significance or usefulness of PyNPase mRNA expression in
oesophageal carcinoma.
MATERIAL AND METHODS
Clinical samples
Fifty-five cases of oesophageal carcinoma were evaluated for this
study. They consisted of 50 male and five female patients with an
average age of 62.0 years (range 40—82). All patients underwent
curative resection. Eleven patients underwent preoperative
chemotherapy using 5-FU, cisplatin, etc. The tumours were located
in the middle oesophagus (n = 32), in the upper oesophagus (n =4 )
or in the lower oesophagus (n = 19) respectively. The stage of
oesophageal cancer was determined pathologically according to
the guidelines of the Japanese Society for Esophageal Diseases
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Summary To clarify the significance of the expression of pyrimidine nucleoside phosphorylase (PyNPase) mRNA as a predictive factor for
the prognosis of patients with oesophageal carcinoma, the PyNPase mRNA in the tumours and normal tissues from 55 resected cases of
oesophageal carcinoma was examined by a reverse transcription polymerase chain reaction (RT-PCR). As a result, a positive correlation was
observed between the tumour/normal (T/N) ratio of the expression of PyNPase mRNA by RT-PCR and that of the enzyme activity of PyNPase
based on the findings of an enzyme linked immunosolvent assay (r = 0.594, P = 0.009). The T/N ratio of the expression of PyNPase mRNA
was significantly higher in the cases with lymph vessel invasion (P = 0.013), lymph node metastasis (P = 0.0016), and an advanced stage of
the disease (P = 0.021) than those without these factors. The patients with a higher T/N ratio of PyNPase mRNA showed significantly worse
prognosis than those with a lower T/N ratio (P = 0.023 with log-rank tests). A multivariate analysis for the cumulative survival rates revealed
that a high T/N ratio of the expression of PyNPase mRNA was independently related to a poor prognosis. These findings suggested that the
determination of PyNPase mRNA by RT-PCR thus appears to be a new useful parameter for identifying both a poor prognosis and a highly
malignant potential of oesophageal carcinoma.
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RNA preparation from tissue specimens
All specimens were taken from fresh tumour tissue, and the adja-
cent normal tissue at a distance of 5 cm from the tumour margin.
Both the tumour and normal tissue specimens were confirmed by a
histological examination. All the samples were immediately stored
at —80°C until used in the following assays. The total RNA was
then extracted according to a method previously described
of acid guanidinium thiocyanate/phenol/chloroform extraction
(Chomczynski and Sacci, 1987). All the samples were treated in
Eppendorf tubes (Eppendorf, Germany).
Reverse transcription
The total RNA was reverse transcribed using random hexamer
primers into the complementary DNA (cDNA) as described previ-
ously (Mori et al, 1995, 1996).
Oligonucleotide primer of PyNPase and GAPDH and
semiquantative detection of mRNA
The preparation of oligonucleotide primers was performed with an
Applied Biosynthesis 394 PCR-Mate DNA Synthesizer. All PCR
primers were selected to span the introns to detect specific mRNA
sequences. The primer sequence of PyNPase has also been described
previously (Mimori et al, 1997). The primer amplified the 464-bp
fragment of PyNPase cDNA. The amplified 450-bp fragment of
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) cDNA was
used as an internal control. An analysis of the semiquantative PCR of
the PyNPase gene was also carried out. The most suitable number of
PCR cycles for amplification of both GAPDH and PyNPase was 26
in the linear range of the curve, as previously determined using
cultured carcinoma cell lines (Mimori et al, 1997).
Polymerase chain reaction
The amplication of PyNPase cDNA was carried out in a total
volume of 25 ml, which included 10´ PCR buffer [100 mM tris-HCl
(pH 8.3), 500 mM potassium chloride, 15 mM magnesium chloride
1% Triton X-100], 25 mM dNTP (mixed dATP, dCTP, dGTP and
dTTP, each 100 mM), 15 mM each PyNPase primer and 1 unit of Taq
DNA polymerase (Promega, Madison, WI, USA). The downstream
primer was end labelled with [g-32P]ATP using T4 polynucleotide
kinase (Takara, Japan). The reactions were subjected to 1 min at
94°C, 2 min at 60°C and 2 min at 72°C. The amplified DNA frag-
ment was then electrophoresed on 1.5% agarose gel containing
ethidium bromide with a DNA molecule weight marker for compar-
ison. The PCR conditions for amplification of GAPDH have been
described previously (Mimori et al, 1997).
Comparison between the level of PyNPase and the
semiquantitation of mRNA
Eighteen samples of the 55 cases were examined for the PyNPase
levels using an enzyme-linked immunosolvent assay (ELISA), as
described by Nishida et al, 1996). In these 18 cases, the enzyme
levels indicated by ELISA was compared with the expression of
PyNPase mRNA by RT-PCR.
Clinical evaluation of PyNPase mRNA
The clinicopathological factors were examined for their
tumour/normal (T/N) ratio of PyNPase mRNA. The stage of
oesophageal cancer was determined pathologically according to
the guidelines of the Japanese Society for Esophageal Diseases
(Japanese Society for Esophageal Diseases, 1992). The cumulative
survival rates after surgical resections were compared using such
variables as age, sex, location of the tumours, depth of tumour
invasion, the histological type, lymph node metastasis, blood
vessel invasion, lymph vessel invasion, stage, and the T/N ratio of
PyNPase mRNA. All the significant variables obtained by a
univariate analysis were then put into the multivariate regression
analysis to identify any independent variables closely related to
the survival rate after operation.
Statistics
The data were expressed as the means ± s.d. Students￿ t-test was
used to determine the statistical significance for univariate
analyses. The survival rates were analysed by the Kaplan—Meier
method (Kaplan and Meier, 1958). A log-rank test (Petro and Pike,
1973) was used to determine the statistically significant differ-
ences between the groups using a univariate analysis, and Cox￿s
proportional hazard model (Cox, 1972) was used for the multi-
variate regression analysis by the Statview 4.5 statistical software
(Abacus Concept, CA, USA).
RESULTS
PyNPase mRNA expression in oesophageal cancer
PyNPase mRNA was detected in all examined cases with
oesophageal carcinoma. All samples were almost equivalent
regarding the expression of GAPDH as an internal control. The
T/N ratio for PyNPase expression was calculated and ranged from
0.51 to 17.76, with an average of 5.83. The median of the T/N ratio
was 5.10.
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Figure 1 The relationship between the tumour/normal (T/N) ratio of the
PyNPase activity as determined by an enzyme-linked immunosolvent assay
(ELISA-T/N) and the T/N ratio of expression of PyNPase mRNA by a reverse
transcription polymerase chain reaction (PCR-T/N) was plotted (n = 18). A
positive correlation was observed between the two assays (r = 0.594,
P = 0.009)Comparison between the PyNPase activity and the
semiquantitation of mRNA
The T/N ratio of PyNPase activity using ELISA ranged from 0.49
to 20.48, with an average of 6.52. A positive correlation was, thus,
observed between the T/N ratio of the PyNPase levels and the
expression of PyNPase mRNA (r = 0.594, P = 0.009) (Figure 1).
Clinicopathological characteristics
Table 1 shows the relationship between the clinicopathological
factors of the patients and the T/N ratio of PyNPase mRNA. There
was no significant difference in the T/N ratio of PyNPase mRNA
in terms of the location of the tumour, the depth of tumour invasion
or the histological type. Patients with lymph node metastasis were,
thus, found to have a significantly higher T/N ratio of PyNPase
mRNA than those without node metastasis (P = 0.016). The T/N
ratio in patients with microscopic lymph vessel invasion was also
significantly higher than that in patients without lymph vessel
invasion (P = 0.013). A more advanced stage of the disease (stage
3 or 4) disclosed a higher T/N ratio (P = 0.021).
Survival after a resection of oesophageal carcinoma
Fifty-five patients with oesophageal cancer were divided into two
groups in association with the T/N ratio of PyNPase mRNA; one
with a T/N ratio <5 and the other with a T/N ratio ‡ 5. Among the
factors examined by a univariate analysis to identify the prognostic
factors for the cumulative survival rate after resection, a high
degree of blood vessel invasion and a high T/N ratio of PyNPase
mRNA were both revealed to be poor prognostic factors. Figure
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Table 1 Relationship between various clinicopathological factors and the
tumour/normal ratio of the pyrimidine nucleoside phosphorylase mRNA in
oesophageal carcinoma
Clinicopathological Number of T/N ratio of
variables patients PyNPase mRNAa P-value
Location of tumour n.s.
Upper oesophagus 19 5.80 ± 2.51
Middle oesophagus 32 6.01 ± 3.64
Lower oesophagus 4 4.86 ± 1.85
Depth of tumour invasion n.s.
Within the adventitia 37 4.96 ± 2.01
Beyond the adventitia 18 6.29 ± 3.53
Histological typeb n.s.
Well differentiated 15 5.36 ± 2.06
Moderately differentiated 25 6.66 ± 3.92
Poorly differentiated 11 5.33 ± 2.61
Unclassified or others 4 4.38 ± 1.99
Lymph node metastasis 0.016
Absent 9 3.55 ± 1.89
Present 46 6.30 ± 3.17
Blood vessel invasion n.s.
Absent 13 5.04 ± 2.65
Present 42 6.11 ± 3.29
Lymph vessel invasion 0.013
Absent 9 3.51 ± 1.91
Present 46 6.31 ± 3.16
Stage of diseasec 0.021
1, 2 10 3.80 ± 1.74
3, 4 45 6.31 ± 3.23
aValues are the means ± standard deviation. bAll were squamous carcinoma
other than unclassified or others which contained small cell carcinoma and
adenocarcinoma. cStage of disease was determined according to the
guidelines of the Japanese Society for Esophageal Diseases (Japanese
Society for Esophageal Diseases, 1992). n.s., no significant difference.
Table 2 Results of a multivariate analysis using Cox’s proportional hazards
model
Variable Coefficient s.e. Relative risk P-value
PyNPase mRNA ³5 1.319 0.566 5.425 0.020
High blood vessel invasiona 1.021 0.497 4.226 0.040
aHigh blood vessel invasion was histologically determined as v2,3 (moderately
or highly invaded to the blood vessel) according to the guidelines of the
Japanese Society for Esophageal Diseases (Japanese Society for
Esophageal Diseases, 1992).
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Figure 2 The cumulative survival rate after resection of oesophageal
carcinoma. (A) Fifty-five patients were divided into two groups according to
the degree of blood vessel invasion defined histologically according to the
guidelines of the Japanese Society for Esophageal Diseases (Japanese
Society for Esophageal Diseases, 1992); low, v0,1 (none or minimally
invaded); and high, v2,3 (moderately or highly invaded to the blood vessel).
The patients in the former group survived significantly longer than those in
the latter groups (P = 0.044 according to the log-rank tests). (B) Fifty-five
patients were divided into two groups according to the tumour/normal (T/N)
ratio of expression of PyNPase mRNA; T/N < 5 and T/N ³ 5. The patients in
the former group survived significantly longer than those in the latter group
(P = 0.023 according to the logrank tests)2A and B shows the cumulative survival rates of the two groups
divided by the degree of blood vessel invasion and the two groups
divided by the value of the T/N ratio of PyNPase mRNA respec-
tively. Patients without or with minimal blood vessel invasion had
a better survival rate than those with higher blood vessel invasion
(P = 0.044). Patients with a T/N ratio of PyNPase mRNA below 5
had a better survival rate than those with a higher T/N ratio
(P = 0.023). There was a significant difference in lymph node
metastasis between the two groups of T/N ratio of PyNPase
mRNA (P = 0.033). Table 2 shows the results of the multivariate
regression analysis for prognosis using the Cox￿s propotional
hazard model. Both blood vessel invasion and the T/N ratio of
PyNPase mRNA were confirmed to be independent prognostic
factors.
DISCUSSION
PyNPase is known to be involved in the invasion and metastasis of
several kinds of tumours. In the present study, the cases with
lymph node metastasis and/or lymph vessel invasion of the cancer
disclosed a high T/N ratio of PyNPase mRNA expression in
oesophageal cancer. This finding is consistent with previous
reports in which malignancies that had high expression of
PyNPase demonstrated a highly aggressive behaviour (Maeda et
al, 1996; Takebayashi et al, 1996a,b; Tanigawa et al, 1996).
Thymidine phosphorylase, equivalent to PyNPase in humans,
has been shown to be identical to a potent angiogenic factor, PD-
ECGF (Ishikawa et al, 1989; Furukawa et al, 1992). Although the
precise mechanism of angiogenesis by PyNPase remains unclear,
previous reports have demonstrated the expression of PyNPase to
be significantly associated with the intratumoral microvessel
counts (Takebayashi et al, 1996a; Tanigawa et al, 1996; Imazono
et al, 1997). Angiogenesis is generally known to play an important
role in the early phase of carcinogenesis. In this study, the number
of the patients in early stage was not sufficient to evaluate the role
of PyNPase mRNA at an early phase of oesophageal carcinoma. In
all examined patients, the expression of PyNPase mRNA did not
correlate with the degree of vascular invasion, however it did
correlate with both lymph vessel invasion and lymph node metas-
tasis. As a result, the expression of PyNPase in oesophageal carci-
noma might, thus, be at least involved in the further invasion and
metastasis of the carcinoma. For further tumour growth and the
development of tumour metastasis, other functions of PyNPase
besides angiogenesis may also play an important role. Another
possible mechanism may be the growth-promoting activity of the
PyNPase/PD-ECGF (Ishikawa et al, 1989).
In addition, we also demonstrated that a higher expression of
PyNPase mRNA in malignant tissue than in normal tissue resulted
in a poor survival rate in the patients with oesophageal cancer.
This fact may be mostly due to a positive correlation between the
high expression of PyNPase mRNA and an advanced clinical
stage. Lymph node metastasis contributes to the advancement of
clinical stage (Sugimachi et al, 1994; Mori et al, 1997). A multi-
variate analysis for the cumulative survival rates revealed that the
higher T/N ratio of the expression of PyNPase mRNA was inde-
pendently related to a poor prognosis. This finding indicates that a
high T/N ratio of PyNPase mRNA may not only be correlated with
tumour aggressiveness, but may also be a useful predictive factor
for a poor prognosis in patients with oesophageal cancer.
An enzyme assay for PyNPase activity using high-performance
liquid chromatography (HPLC) requires a large amount of sample
of more than 100 mg (Eda et al, 1993), whereas, in contrast, the
RT-PCR method for detecting mRNA can be carried out using a
very small sample including biopsy specimens (Hirokoshi et al,
1992; Mimori et al, 1997). Nishida et al (1996) suggested that
there was good correlation between the enzyme levels of PyNPase
measured by ELISA and the enzyme activity measured by HPLC.
Our present study demonstrated a positive correlation between the
PyNPase levels determined by the ELISA assay and the expres-
sion of PyNPase mRNA regarding the T/N ratio in oesophageal
cancer. Therefore, the RT-PCR method allows us to determine the
PyNPase status preoperatively from biopsy specimens.
The preoperative evaluation of the PyNPase condition of
tumours is important, not only for determining the appropriate
operative procedures but also for selecting the optimal anti-cancer
drugs for adjutant chemotherapy. An extended resection may be
necessary for patients with a probable poor prognosis predictable
by the expression of PyNPase mRNA. An anti-cancer drug, 5¢-
DFUR, is a prodrug of 5-FU, and is converted to 5-FU by PyNPase
(Ishitsuka et al, 1980; Eda et al, 1993). In fact, the anti-tumour
effect of 5¢-DFUR depends on the sensitivity of the tumour tissue
to 5-FU. 5¢-DFUR may be effective on carcinomas with higher
activity of PyNPase and with sensitivity to 5-FU because of the
possible selective cytotoxicity against tumour tissue of this anti-
tumour drug, with a lower toxicity against normal tissue.
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